Whales with a lot of money to spend have taken a noticeably bearish stance on Guardant Health.
Looking at options history for Guardant Health GH we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 33% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $157,232 and 9, calls, for a total amount of $450,285.
Projected Price Targets
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $15.0 to $30.0 for Guardant Health over the last 3 months.
Volume & Open Interest Development
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Guardant Health's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Guardant Health's whale trades within a strike price range from $15.0 to $30.0 in the last 30 days.
Guardant Health 30-Day Option Volume & Interest Snapshot
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GH | CALL | SWEEP | NEUTRAL | 05/17/24 | $4.4 | $3.7 | $4.0 | $20.00 | $80.0K | 9.0K | 527 |
| GH | CALL | TRADE | BULLISH | 05/17/24 | $1.75 | $1.35 | $1.6 | $22.50 | $80.0K | 2.1K | 617 |
| GH | CALL | SWEEP | NEUTRAL | 05/17/24 | $1.7 | $1.5 | $1.5 | $22.50 | $75.0K | 2.1K | 617 |
| GH | PUT | SWEEP | BEARISH | 01/17/25 | $3.1 | $2.9 | $3.1 | $20.00 | $57.6K | 2.0K | 0 |
| GH | CALL | SWEEP | BULLISH | 05/17/24 | $4.3 | $3.4 | $4.25 | $20.00 | $56.9K | 9.0K | 315 |
About Guardant Health
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Having examined the options trading patterns of Guardant Health, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Current Position of Guardant Health
- Currently trading with a volume of 2,685,790, the GH's price is up by 6.77%, now at $23.89.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 80 days.
What Analysts Are Saying About Guardant Health
In the last month, 3 experts released ratings on this stock with an average target price of $28.666666666666668.
- An analyst from Goldman Sachs has decided to maintain their Buy rating on Guardant Health, which currently sits at a price target of $28.
- Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Guardant Health with a target price of $30.
- An analyst from Craig-Hallum has revised its rating downward to Buy, adjusting the price target to $28.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Guardant Health, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
